Trial Profile
A Phase I, Open Label Study of the Effects of Lean Body Mass (LBM) and Proton Pump Inhibitors (PPIs) on Pharmacokinetics and Safety of Regorafenib (BAY 73-4506) in Cancer Patients
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase I
Latest Information Update: 25 Jun 2021
Price :
$35
*
At a glance
- Drugs Regorafenib (Primary) ; Pantoprazole
- Indications Solid tumours
- Focus Pharmacokinetics
- 18 Jun 2021 Status changed from not yet recruiting to withdrawn prior to enrolment.
- 04 Jan 2016 Planned initiation date changed from 1 Jun 2015 to 1 Mar 2016, according to ClinicalTrials.gov record.
- 15 May 2015 New trial record